STIM1 Deficiency (CRAC Channelopathy) — Comprehensive Disease Characterization Report

Disease: STIM1 Deficiency MONDO ID: MONDO:0013008 OMIM: #612783 (Immunodeficiency 10, IMD10) Category: Mendelian, autosomal recessive Gene: STIM1 (Stromal Interaction Molecule 1; HGNC:11386; NCBI Gene 6786; OMIM *605921; chromosome 11p15.4)

Summary

STIM1 deficiency is an ultra-rare, autosomal-recessive CRAC (Ca²⁺-release-activated Ca²⁺) channelopathy caused by biallelic loss-of-function (LOF) variants in STIM1, the endoplasmic-reticulum (ER) Ca²⁺ sensor that activates the plasma-membrane channel ORAI1. When STIM1 cannot sense ER Ca²⁺ depletion or engage ORAI1, store-operated Ca²⁺ entry (SOCE) is abolished. Because SOCE is a near-universal cellular signaling module, its loss produces a congenital multisystem syndrome: a SCID-like combined immunodeficiency accompanied — paradoxically — by autoimmunity and lymphoproliferation, together with non-immune features including muscular hypotonia/myopathy, anhidrotic (anhydrotic) ectodermal dysplasia with defective sweating, dental enamel hypomineralization, and pupillary/iris abnormalities (mydriasis). The syndrome is shared with recessive ORAI1 deficiency, its molecular partner, and together they define "CRAC channelopathy" (PMID: 26469693).

The core causal chain is well established: biallelic LOF STIM1 mutation → loss/nonfunction of STIM1 protein → failure of the luminal EF-hand/SAM (EF-SAM) domain to sense ER Ca²⁺ depletion and oligomerize → failure to translocate to ER–plasma-membrane junctions and gate ORAI1 via the CRAC activation domain (CAD) → CRAC channels remain closed → absent SOCE → collapse of the downstream Ca²⁺–calmodulin–calcineurin–NFAT transcriptional axis in lymphocytes (impaired cytokine production despite normal lymphocyte development) plus failure of Ca²⁺-dependent functions in muscle, sweat gland, ameloblast, and iris smooth muscle. Critically, STIM1 deficiency (LOF) is the mechanistic mirror image of dominant STIM1 gain-of-function (GOF), which causes constitutive SOCE and the tubular aggregate myopathy (TAM) / Stormorken syndrome spectrum — a distinction essential for correct classification and rational therapy.

The only curative therapy for the immunodeficiency is allogeneic hematopoietic stem cell transplantation (HSCT), as for other combined immunodeficiencies; HSCT does not correct the non-hematopoietic (muscle, ectodermal, dental) features, which are managed supportively. A splice-correcting antisense oligonucleotide (ASO) that restores STIM1 splicing/function in patient cells has been demonstrated as a proof-of-concept, mutation-specific therapy (PMID: 38977117). Untreated, the disease is life-threatening in infancy/early childhood from recurrent, severe, and opportunistic infections, compounded by autoimmune cytopenias and lymphoproliferation.

1. Disease Information

STIM1 deficiency is a primary (inborn) error of immunity classified as a CRAC channelopathy. It is defined by the loss of store-operated Ca²⁺ entry (SOCE) secondary to biallelic loss-of-function of the ER Ca²⁺ sensor STIM1. As stated in the landmark review, "CRAC channelopathy is caused by loss-of-function mutations in ORAI1 and STIM1 that abolish CRAC channel function and SOCE; it is characterized by severe combined immunodeficiency (SCID)-like disease, autoimmunity, muscular hypotonia, and ectodermal dysplasia, with defects in sweat gland function and dental enamel formation" (PMID: 26469693).

Key identifiers:

Synonyms / alternative names: Immunodeficiency 10 (IMD10); STIM1 loss-of-function; CRAC channelopathy (STIM1 type); combined immunodeficiency with autoimmunity due to STIM1 deficiency; store-operated calcium entry (SOCE) deficiency.

Source of information: The disease is characterized almost entirely from individual patient reports and small consanguineous kindreds (fewer than ~15 families reported worldwide) combined with in vitro functional studies and animal models — not from aggregated EHR-scale registries. The evidence base is therefore case-based human clinical data plus mechanistic model-organism and cellular studies.

2. Etiology

Primary cause — purely genetic. STIM1 deficiency is caused solely by biallelic recessive loss-of-function variants in STIM1 that abolish SOCE. There are no environmental, infectious, or toxic causes, no somatic contribution, and no established modifier genes or disease-specific epigenetic changes. Infections in patients are downstream consequences of the immunodeficiency, not causes (Finding F012).

Genetic risk factors. The causal genetic events are germline biallelic LOF variants (homozygous or compound heterozygous). Reported variants include nonsense/frameshift alleles (e.g., c.685delT, p.Phe229Leufs12, causing complete protein loss; PMID: 33733462) and splice-site variants (e.g., NM_003156 c.792-3C>G producing exon-7 skipping/intron retention with impaired SOCE; PMID: 38977117). Consanguinity is a strong risk factor*, as expected for a rare recessive disorder — e.g., "we studied two siblings from a consanguineous Syrian family" (PMID: 33733462).

Environmental / lifestyle risk factors: None identified. Protective factors (genetic or environmental): None established.

Gene–environment interactions: None mechanistically established. The only "interaction" is that pathogen exposure unmasks and drives the clinical immunodeficiency, but pathogens are not co-causal.

LOF vs GOF dichotomy (etiologic classification). STIM1 deficiency (recessive LOF) is the mechanistic opposite of autosomal-dominant STIM1 gain-of-function, which causes constitutive CRAC activation and the TAM/Stormorken spectrum: "By contrast, autosomal dominant gain-of-function mutations in ORAI1 and STIM1 result in constitutive CRAC channel activation, SOCE, and increased intracellular Ca²⁺ levels that are associated with an overlapping spectrum of diseases, including nonsyndromic tubular aggregate myopathy (TAM) and York platelet and Stormorken syndromes" (PMID: 26469693). "Loss- and gain-of-function gene mutations in ORAI1 and STIM1 in human patients cause distinct disease syndromes" (PMID: 26469693).

3. Phenotypes

STIM1 deficiency is a congenital multisystem disorder. The immunological phenotype (combined immunodeficiency + immune dysregulation) is essentially universal; individual non-immune features are variably present (variable expressivity). Frequencies are qualitative given the very small number of reported patients (F011).

Key supporting quotes: "in the case of STIM1 deficiency, autoimmunity and lymphoproliferative disease. The immunodeficiency in these patients is due to a severe defect in T cell activation but not in lymphocyte development" (PMID: 20189884); the disease "is dominated by severe immunodeficiency and autoimmunity due to impaired SOCE" (PMID: 22615435); "muscular hypotonia, and ectodermal dysplasia, with defects in sweat gland function and dental enamel formation" (PMID: 26469693); the expanded phenotype "presenting with muscle weakness, hyperlaxity, elastic skin, tooth abnormalities, dysmorphic facies, hypoplastic patellae and history of respiratory infections" (PMID: 33733462).

Quality-of-life impact: Severe. Life-threatening infections dominate infancy; chronic autoimmune cytopenias require transfusion/immunosuppression; anhidrosis causes heat intolerance and hyperthermia risk; enamel defects affect dentition and nutrition; hypotonia/myopathy impairs motor development. Formal EQ-5D/SF-36 data are not available for this ultra-rare disease.

Severity/progression: Immune features are severe and life-threatening but treatable by HSCT; non-immune features are largely congenital and static/non-progressive rather than degenerative.

4. Genetic / Molecular Information

Causal gene: STIM1 (HGNC:11386; NCBI Gene 6786; OMIM *605921; UniProt Q13586), encoding the single-pass ER-membrane Ca²⁺ sensor Stromal Interaction Molecule 1.

Pathogenic variants (biallelic, recessive):

Supporting quotes: "we have identified a new homozygous frameshift mutation in STIM1: c.685delT [p.(Phe229Leufs*12)], leading to a complete loss of STIM1 protein" (PMID: 33733462); "a novel homozygous mutation, NM_003156 c.792-3C > G, in STIM1 in a patient with a clinical profile of CRAC channelopathy, including immune system deficiencies and muscle weakness" (PMID: 38977117).

Variant classification: Reported LOF variants are pathogenic (ACMG/AMP), supported by functional evidence of abolished SOCE (PS3), null variant type (PVS1), and segregation in consanguineous families.

Variant types: Nonsense, frameshift, and splice-site (all loss-of-function). Allele frequency: Extremely rare/private; not reported at appreciable frequency in gnomAD (consistent with recessive, ultra-rare disease). Origin: Germline only; no somatic contribution. Functional consequence: Loss of function (loss of ER Ca²⁺ sensing and ORAI1 gating → absent SOCE). By contrast, dominant TAM/Stormorken alleles are gain-of-function (F012).

Modifier genes / epigenetics / chromosomal abnormalities: None established for STIM1 deficiency. The paralog STIM2 (lower activation threshold) is a plausible but untested compensatory modifier in humans. No disease-specific methylation/histone signatures or large structural rearrangements are reported.

5. Environmental Information

No environmental, lifestyle, or infectious etiologic factors contribute to disease causation. STIM1 deficiency is a monogenic recessive disorder. Infectious agents (viral, bacterial, fungal) are downstream complications of the immunodeficiency, not triggers. No toxin, radiation, occupational, or dietary factor has been implicated in onset or severity (F012).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic LOF STIM1 mutation → loss or nonfunction of STIM1 protein (demonstrated; complete protein loss for c.685delT, PMID: 33733462).
2. Loss of ER Ca²⁺ sensing: the luminal EF-hand/SAM (EF-SAM) domain can no longer detect ER Ca²⁺ depletion or relieve autoinhibition to oligomerize (demonstrated biophysically: "the STIM1 Ca²⁺-binding EF-hand and the STIM2 SAM domain are major contributors to the autoinhibition of oligomerization", PMID: 21217057) → leads to
3. Failure of STIM1 conformational activation and translocation to ER–plasma-membrane junctions; the CRAC activation domain (CAD/CC1+CAD) cannot form store-dependent oligomers ("Addition of CC1 + CAD, but not CC1 alone, enables the formation of stable store-dependent oligomers. Within the CAD, both CC2 and C-terminal residues contribute to oligomer formation", PMID: 20375143) → results in
4. Failure to bind and gate ORAI1, the pore-forming CRAC subunit (normal mechanism: "ORAI1 (or CRACM1) acts as the pore-forming subunit of the CRAC channel in the plasma membrane. Stromal interaction molecule (STIM) 1 is localized in the ER, senses [Ca²⁺]ER, and activates the CRAC channel upon store depletion by binding to ORAI1", PMID: 20111871) → leads to
5. CRAC channels remain closed → absent store-operated Ca²⁺ entry (SOCE) and no I_CRAC (demonstrated in patient cells: "Calcium influx analysis revealed impaired SOCE in the patient cells", PMID: 38977117). This is the central, fully penetrant cellular lesion. The chain then branches across tissues:

Branch A — Immune (demonstrated): Absent sustained Ca²⁺ → failure of the Ca²⁺–calmodulin–calcineurin–NFAT axis → NFAT cannot be dephosphorylated/translocate to the nucleus → cytokine gene transcription (e.g., IL-2) fails → defective T-cell activation/effector function despite normal lymphocyte development ("Ca²⁺-calcineurin-nuclear factor of activated T cells (NFAT) signalling pathway", PMID: 23483280; NFAT nuclear import was the discovery readout for ORAI1, "promoting the immune response to pathogens by activating the transcription factor NFAT", PMID: 16582901) → combined immunodeficiency. Concurrent failure of Treg/iNKT function and loss of tolerance → autoimmunity + lymphoproliferation (F002, F006, F010).

Branch B — Skeletal muscle (inferred / model-supported): Loss of SOCE-dependent Ca²⁺ replenishment → impaired muscle Ca²⁺ handling → hypotonia/myopathy.

Branch C — Eccrine sweat gland (inferred): Loss of SOCE in secretory epithelium → anhidrosis / ectodermal dysplasia.

Branch D — Ameloblasts/enamel organ (model-supported): Loss of SOCE in ameloblasts → defective enamel mineralization → enamel hypoplasia ("Stim1 Regulates Enamel Mineralization and Ameloblast Modulation", PMID: 28732182; SOCE impairment in enamel cells, PMID: 28352661).

Branch E — Iris smooth muscle (inferred): → mydriasis / pupillary abnormality.

1. Branch A extends further to STIM1–NFAT synergy with STAT1 controlling T-bet / Th1 differentiation (PMID: 39984734) and to Ca²⁺-dependent T-cell metabolic reprogramming (PMID: 33103016).

Detail by category

• Molecular pathways: SOCE / CRAC signaling → Ca²⁺–calcineurin–NFAT (canonical effector); STIM1→STAT1→T-bet (Th1). GOF of the same pathway drives STIM1/Orai1/NFAT-mediated pathology in other contexts (e.g., cardiac; PMID: 42285689), confirming the pathway's centrality.
• Cellular processes: T-cell activation, cytokine transcription, regulatory-T-cell stability, NK/iNKT cytotoxicity, macrophage/monocyte chemotaxis (STIM1-dependent; PMID: 38815866).
• Protein dysfunction: Loss of function of STIM1 — failure of the EF-SAM Ca²⁺ sensor and CAD gating module (structural/biophysical basis: PMID: 21217057, PMID: 20375143, PMID: 18166150).
• Immune involvement: Combined immunodeficiency (defective T/NK/B/iNKT/Treg) plus autoimmunity — "It is dominated by severe immunodeficiency and autoimmunity due to impaired SOCE and defects in the function of several lymphocyte subsets. These include CD8⁺ T cells, CD4⁺ effector and regulatory T cells, natural killer (NK) cells and B cells" (PMID: 22615435). Reduced iNKT/Treg cells drive autoimmunity ("ORAI1 mutations were associated with strongly reduced numbers of invariant natural killer T and regulatory T (Treg) cells", PMID: 29155098).
• Biochemical abnormality: Ion channel defect (CRAC channelopathy) — absent I_CRAC/SOCE.
• Subcellular compartments (GO CC): ER membrane (GO:0005789), ER–plasma membrane contact site (GO:0140268), plasma membrane (GO:0005886).

Suggested GO biological-process terms: store-operated calcium entry (GO:0002115), calcium ion transmembrane import into cytosol (GO:0097553), positive regulation of T-cell activation (GO:0050870), NFAT protein import into nucleus. Suggested CL terms: T cell (CL:0000084), CD8-positive αβ T cell (CL:0000625), regulatory T cell (CL:0000815), natural killer cell (CL:0000623), B cell (CL:0000236), ameloblast (CL:0000059), skeletal muscle fiber (CL:0008002). CHEBI: calcium(2+) (CHEBI:29108).

7. Anatomical Structures Affected

Primary organ systems and structures (F007):

Cell populations targeted: CD8⁺ and CD4⁺ effector T cells, regulatory T cells, iNKT cells, NK cells, B cells, ameloblasts, skeletal myofibers, eccrine secretory epithelial cells, iris smooth muscle cells.

Subcellular compartments: ER membrane (STIM1 residence) and ER–plasma-membrane junctions where CRAC channels assemble (GO:0140268).

Supporting quotes: "immunodeficiency, muscular hypotonia and anhydrotic ectodermal dysplasia" (PMID: 20189884); "muscular hypotonia, and ectodermal dysplasia, with defects in sweat gland function and dental enamel formation. The latter defect emphasizes an important role of CRAC channels in tooth development" (PMID: 26469693). Lateralization: Systemic/bilateral, not lateralized.

8. Temporal Development

• Onset: Congenital to early infancy. The immunodeficiency typically manifests within the first months of life as recurrent/severe/opportunistic infections (SCID-like), consistent with the T-cell activation defect (PMID: 20189884).
• Onset pattern: Immune disease — subacute/insidious then severe with infection; non-immune features (hypotonia, anhidrosis, enamel/iris defects) present congenitally.
• Progression: Immune disease is progressive/life-threatening if untreated; non-immune features are largely static (non-degenerative). Autoimmune cytopenias and lymphoproliferation follow a chronic, relapsing course.
• Duration: Chronic/lifelong; the immunodeficiency is curable by HSCT, but ectodermal, dental, and muscle features persist.
• Critical period / window of intervention: Early infancy — analogous to SCID, early HSCT before infectious complications improves outcome. Mutation-specific ASO therapy would similarly be most valuable early.

9. Inheritance and Population

• Inheritance: Autosomal recessive. Biallelic (homozygous or compound heterozygous) LOF variants are required; heterozygous carriers are clinically asymptomatic although their T cells show partially reduced SOCE — a demonstrated gene-dosage effect in the analogous ORAI1 channelopathy: "Although heterozygous carriers of the mutation show no clinical symptoms of immunodeficiency, store-operated Ca²⁺ entry in their T cells is impaired, suggesting a gene-dosage effect of the mutation" (PMID: 19075015).
• Penetrance / expressivity: Loss of SOCE/CRAC current is a fully penetrant cellular phenotype, but clinical expressivity is variable — "we confirmed that the complete loss of STIM1 function is not always associated with severe immune disorders" (PMID: 33733462).
• Consanguinity: Strongly associated; reported families are frequently consanguineous (e.g., "we studied two siblings from a consanguineous Syrian family", PMID: 33733462).
• Epidemiology: Ultra-rare. Fewer than ~15 STIM1-deficient families reported worldwide; no reliable population prevalence/incidence estimate exists. Carrier frequency: Not established; variants are private/very rare.
• Founder effects, anticipation, germline mosaicism: None established. Anticipation is not expected (not a repeat-expansion disorder).
• Sex ratio: No strong sex bias reported (autosomal). Geographic distribution: Case reports skew to populations with higher consanguinity rates, reflecting recessive inheritance rather than true regional endemicity.

10. Diagnostics

Diagnostic workflow (F008): combine a functional SOCE/CRAC assay with molecular genetic confirmation.

1. Functional biomarker (highly specific): A store-operated Ca²⁺ entry (SOCE) assay on patient T cells or fibroblasts shows abolished/impaired Ca²⁺ influx and absent I_CRAC. "Calcium influx analysis revealed impaired SOCE in the patient cells, indicating a loss of STIM1 function" (PMID: 38977117). Re-expression of wild-type protein rescues SOCE, confirming causality (rescue paradigm in the CRAC channelopathy spectrum: "expression of wild-type Orai1 in SCID T cells restores store-operated Ca²⁺ influx and the CRAC current", PMID: 16582901).
2. Molecular diagnosis: Whole-exome sequencing ("Using exome sequencing, we have identified a new homozygous frameshift mutation in STIM1", PMID: 33733462), targeted single-gene STIM1 testing, or primary-immunodeficiency gene panels; historically supported by SNP-array linkage/genome-wide screens ("a modified linkage analysis with single-nucleotide polymorphism arrays, and a Drosophila RNA interference screen", PMID: 16582901). WGS is also applicable.
3. Immunologic workup: Normal/near-normal lymphocyte numbers and development but defective T-cell activation and cytokine production; reduced Treg/iNKT cells; autoimmune cytopenias (hemolytic anemia, thrombocytopenia) on CBC/DAT.
4. Other exam findings: Muscle hypotonia; anhidrosis (sweat testing); enamel defects on dental exam; mydriasis on eye exam.

Differential diagnosis: Typical SCID (STIM1 deficiency is distinguished by normal lymphocyte development plus prominent autoimmunity/lymphoproliferation plus ectodermal/dental/muscle features); ORAI1 deficiency (partner gene, clinically near-identical — resolve by gene testing); anhidrotic ectodermal dysplasia with immunodeficiency (NEMO/IKBKG); other combined immunodeficiencies with immune dysregulation. STIM1 gain-of-function TAM/Stormorken syndrome is the key mirror-image differential (myopathy + thrombocytopenia + miosis, dominant).

Screening: Newborn TREC-based SCID screening may not reliably detect STIM1 deficiency because T-cell numbers/development are relatively preserved; cascade genetic testing and prenatal/carrier testing are appropriate in known families.

11. Outcome / Prognosis

• Untreated prognosis: Poor and life-threatening in infancy/early childhood. The SCID-like immunodeficiency causes recurrent, severe, and opportunistic viral, bacterial, and fungal infections; autoimmunity (hemolytic anemia, thrombocytopenia) and lymphoproliferation add substantial morbidity and mortality (F009, F011).
• Curative treatment outcome: Allogeneic HSCT can cure the hematopoietic/immune disease (see §12) but does not correct non-hematopoietic features (muscle hypotonia, anhidrosis/ectodermal dysplasia, dental enamel defects), which persist and require supportive management.
• Morbidity / disability: Chronic — heat intolerance from anhidrosis, motor impairment from hypotonia/myopathy, dental morbidity, and autoimmune cytopenia burden.
• Prognostic factors: Timing of diagnosis and HSCT, severity/control of infections and autoimmunity, and donor availability. No validated molecular prognostic biomarkers beyond the underlying null genotype.
• Quality of life: No formal EQ-5D/SF-36/PROMIS datasets exist for this ultra-rare disease.

12. Treatment

Definitive therapy — Allogeneic HSCT (NCIT: Hematopoietic Stem Cell Transplantation, C15431). Because the immunodeficiency is intrinsic to hematopoietic cells, allogeneic HSCT is the only curative option for the immune disease, as for other SCID/combined immunodeficiencies. A CRAC-channelopathy patient (ORAI1 deficiency) is documented within the inborn-errors-of-immunity HSCT pathway, receiving virus-specific T cells pre-transplant ("1 ORAI1 deficiency"; PMID: 33462728). HSCT does not correct muscle, ectodermal, or dental manifestations (F009).

Supportive / symptomatic care: - Immunoglobulin replacement (NCIT: Intravenous Immunoglobulin Therapy). - Antimicrobial/antiviral/antifungal prophylaxis. - Immunosuppression for autoimmune cytopenias and lymphoproliferation (corticosteroids, etc.). - Heat-avoidance and thermoregulatory management for anhidrosis. - Dental care for enamel defects; physiotherapy for hypotonia/weakness.

Experimental / mutation-specific therapy: A splice-correcting antisense oligonucleotide (ASO) restored STIM1 splicing and function in patient cells: "We developed an antisense oligonucleotide treatment that improves STIM1 splicing and highlighted its potential as a therapeutic approach" (PMID: 38977117). This is genotype-specific (applicable to splice-altering alleles).

Pharmacology note: CRAC-channel modulators are being developed largely for gain-of-function/inflammatory indications — Orai blockers would be irrational for LOF deficiency (a channel activator, not a blocker, would conceptually be required). Selective Orai blockers (e.g., indazole/pyrazole scaffolds; PMID: 39232360) are therefore relevant to the disease's differential/GOF spectrum but not to treating LOF STIM1 deficiency. Pharmacogenomics: Not applicable.

13. Prevention

• Primary prevention: Not possible for the monogenic disease itself. Genetic counseling for consanguineous families and families with a prior affected child is central; recurrence risk is 25% per pregnancy (autosomal recessive).
• Reproductive options: Carrier testing, preimplantation genetic diagnosis (PGD), and prenatal testing in known families.
• Secondary prevention: Early molecular diagnosis and cascade testing to enable timely HSCT before infectious complications. Standard newborn SCID (TREC) screening may miss STIM1 deficiency because T-cell numbers are relatively preserved — a diagnostic gap.
• Tertiary prevention (complication avoidance): Infection prophylaxis, IVIG, immunosuppression for autoimmunity, heat-avoidance for anhidrosis, dental surveillance, and vaccination caution (live vaccines contraindicated in combined immunodeficiency).
• Immunization / public health / environmental interventions: Not applicable as disease modifiers (non-infectious genetic disorder), beyond standard protection of immunocompromised patients.

14. Other Species / Natural Disease

• Orthologs: Mouse Stim1 (NCBI Gene 20866; species Mus musculus, NCBI:txid10090); orthologs are conserved broadly across vertebrates. The STIM/Orai SOCE machinery is evolutionarily ancient — originally characterized in non-excitable cells and via Drosophila RNAi screens (PMID: 16582901).
• Natural disease in other species (OMIA/veterinary): No well-established naturally occurring STIM1-deficiency disease has been characterized in companion animals or wildlife in the reviewed literature; the human disease is modeled mechanistically in engineered mice.
• Comparative biology: The SOCE pathway is highly conserved, so engineered Stim1 loss in mice recapitulates key aspects of the human disease (see §15). Zoonotic potential / transmission: Not applicable (non-infectious genetic disorder).

15. Model Organisms

Mouse (Mus musculus) is the principal model (F006):

Supporting quote: "STIM1 deficiency significantly impaired the generation of neuroantigen-specific T cell responses in vivo with reduced Th1/Th17 responses, resulting in complete protection from EAE" (PMID: 20028655).

Model types available: Conditional/tissue-specific knockouts (T-cell, Treg, ameloblast), global knockdowns, patient-derived primary cells and fibroblasts; iPSC/organoid models are feasible but not prominently reported. Model limitations: Global Stim1 knockout is largely perinatal-lethal in mice, necessitating conditional models; single-tissue models capture individual branches (immune, dental) rather than the full multisystem human syndrome. Applications: Dissecting SOCE-dependent T-cell activation, tolerance, enamel biology, and testing splice-correction/rescue strategies.

Mechanistic Model / Synthesis

   Biallelic LOF STIM1 mutation (nonsense / frameshift / splice)
                        │  (loss / nonfunction of STIM1 protein)
                        ▼
   EF-SAM domain cannot sense ER Ca2+ depletion → no autoinhibition relief
                        │
                        ▼
   No STIM1 oligomerization / CAD-mediated translocation to ER–PM junctions
                        │
                        ▼
   ORAI1 not gated → CRAC channels CLOSED → ABSENT SOCE (I_CRAC = 0)
                        │
        ┌───────────────┼───────────────┬───────────────┬──────────────┐
        ▼               ▼               ▼               ▼              ▼
 Ca2+–calcineurin   Muscle Ca2+     Sweat gland      Ameloblast      Iris smooth
 –NFAT axis fails   handling ↓      secretion ↓      SOCE ↓          muscle ↓
        │               │               │               │              │
        ▼               ▼               ▼               ▼              ▼
 Cytokine genes    Hypotonia /     Anhidrosis /     Enamel          Mydriasis
 not transcribed   myopathy        ectodermal       hypoplasia
 (IL-2 etc.)                       dysplasia
        │
        ▼
 Combined immunodeficiency (defective T/NK/B/iNKT)
 + Treg/iNKT dysfunction → autoimmunity + lymphoproliferation
        │
        ▼
 Recurrent/opportunistic infections + autoimmune cytopenias
 (life-threatening in infancy; curable by HSCT — immune branch only)

The unifying principle is that STIM1 is the obligatory ER Ca²⁺ sensor for SOCE, and its loss removes a single node whose downstream Ca²⁺ signal is required across many terminally differentiated cell types. The immune branch is clinically dominant and the only one correctable by HSCT, because it is hematopoietic-cell-intrinsic; the muscle, ectodermal, and dental branches arise in non-hematopoietic tissues and therefore persist after transplant. The LOF↔GOF mirror (deficiency vs TAM/Stormorken) is the organizing classification insight: both perturb the same Ca²⁺ set-point but in opposite directions, and both produce myopathy — underscoring how tightly skeletal muscle depends on SOCE homeostasis.

Evidence Base

Evidence source types: Human clinical (case reports/kindreds: 33733462, 38977117, 20189884, 19075015); in vitro/biophysical (21217057, 20375143, 18166150, 20111871); model organism (20028655, 42421074, 38815866, 28732182, 28352661); computational/structural (EF-SAM/CAD studies).

Limitations and Knowledge Gaps

1. Ultra-rare, case-based evidence. Fewer than ~15 STIM1-deficient families are reported; there are no population prevalence/incidence figures, no natural-history cohorts, and no formal QoL datasets. Frequencies of individual phenotypes are qualitative.
2. Cross-gene extrapolation. Several mechanistic and treatment points (carrier gene-dosage effect, HSCT pathway, iNKT/Treg reduction) draw on the closely related ORAI1 deficiency because STIM1-specific human data are sparse. ORAI1 and STIM1 are obligate partners, so extrapolation is well justified but not identical.
3. Non-immune branches are partly model-inferred. The muscle, sweat-gland, and iris branches are strongly inferred from SOCE biology and mouse data; direct human tissue-level mechanistic proof is limited. Enamel involvement is best supported (mouse ameloblast models).
4. Variable expressivity is unexplained. The observation that complete STIM1 loss is "not always associated with severe immune disorders" (PMID: 33733462) lacks a defined modifier mechanism (possibly STIM2 compensation — untested in humans).
5. Therapeutics are early. HSCT experience specific to STIM1 (vs ORAI1) is limited; the splice-correcting ASO is in vitro proof-of-concept only, with no clinical trial (no NCT identifier established).
6. No investigational primary dataset was analyzed in this study; conclusions are literature-synthesis based.

Proposed Follow-up Experiments / Actions

1. Establish an international STIM1-deficiency registry to quantify prevalence, genotype–phenotype correlations, penetrance/expressivity of each organ branch, and long-term HSCT vs non-immune outcomes.
2. Test STIM2 as a modifier of expressivity in patient cells and mouse models (e.g., STIM2 dosage rescue of residual SOCE), to explain why some complete-LOF patients lack severe immune disease.
3. Advance the splice-correcting ASO toward preclinical/IND studies for splice-altering alleles (e.g., c.792-3C>G), and evaluate gene-replacement or base/prime-editing for null alleles.
4. Systematic multi-tissue phenotyping in conditional mouse models (muscle-, sweat-gland-, and iris-specific Stim1 KO) to convert inferred branches into demonstrated mechanisms and to test whether HSCT alone can address any non-immune feature.
5. Improve newborn screening — because TREC screening may miss STIM1 deficiency (preserved T-cell numbers), evaluate functional SOCE-based or panel-based add-ons for high-risk/consanguineous populations.
6. Prospective HSCT outcome study in CRAC channelopathy (STIM1 + ORAI1) to define conditioning, timing, and the fate of autoimmunity/lymphoproliferation post-transplant.

Report compiled from 12 confirmed findings and 48 reviewed papers across 5 investigation iterations. Evidence is human clinical (case reports/kindreds), in vitro/biophysical, and model-organism; primary population-scale data are unavailable for this ultra-rare disorder.